Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus bevacizumab in first-line advanced hepatocellular carcinoma
CTR20200190Phase 2Active
- Sponsor
- Junshi Biosciences
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Junshi Biosciences. Started Feb 2020; status: active.
02
Drugs
toripalimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20200190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200190.